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Abstract: Human immunodeficiency virus (HIV) infection is associated with an increased risk of non-
Hodgkin lymphoma (NHL). Even in the era of suppressive antiretroviral treatment, HIV-infected individ-
uals remain at higher risk of developing NHL compared to the general population. To identify potential
genetic risk loci, we performed case-control genome-wide association studies and a meta-analysis across
three cohorts of HIV+ patients of European ancestry, including a total of 278 cases and 1924 matched
controls. We observed a significant association with NHL susceptibility in the C-X-C motif chemokine
ligand 12 (CXCL12) region on chromosome 10. A fine mapping analysis identified rs7919208 as the most
likely causal variant (P = 4.77e-11), with the G>A polymorphism creating a new transcription factor
binding site for BATF and JUND. These results suggest a modulatory role of CXCL12 regulation in the
increased susceptibility to NHL observed in the HIV-infected population.
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Human immunodeficiency virus (HIV) infection is associated with anincreased risk of non-Hodgkin lymphoma (NHL). Even in the era ofsuppressive antiretroviral treatment, HIV-infected individuals
remain at higher risk of developing NHL compared to the general popula-
tion. In order to identify potential genetic risk loci, we performed case-con-
trol genome-wide association studies and a meta-analysis across three
cohorts of HIV-infected patients of European ancestry, including a total of
278 cases and 1,924 matched controls. We observed a significant associa-
tion with NHL susceptibility in the C-X-C motif chemokine ligand 12
(CXCL12) region on chromosome 10. A fine mapping analysis identified
rs7919208 as the most likely causal variant (P=4.77e-11), with the G>A
polymorphism creating a new transcription factor binding site for BATF
and JUND. These results suggest a modulatory role of CXCL12 regulation
in the increased susceptibility to NHL observed in the HIV-infected popu-
lation.
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Introduction
Human immunodeficiency virus (HIV) infection is
associated with a markedly increased risk of several
types of cancer compared to the general population.1–3
This elevated cancer risk can be attributed partly to viral-
induced immunodeficiency, frequent co-infections with
oncogenic viruses (e.g., Epstein-Barr virus [EBV], hepati-
tis B and hepatitis C viruses, human herpesvirus 8 [HHV-
8] and papillomavirus), and increased prevalence of tradi-
tional risk factors such as smoking.4,5 However, all of
these risk factors may not entirely explain the excess
cancer burden seen in the HIV-infected (HIV+) popula-
tion.5,6
A previous study performed in the Swiss HIV Cohort
Study (SHCS) identified two AIDS-defining cancers,
Kaposi sarcoma and non-Hodgkin lymphoma (NHL) as
the main types of cancer found among HIV+ patients
(NHL representing 34% of all identified cancers).4 The
relative risk of developing NHL in HIV+ patients was
highly elevated compared to the general population
(period-standardized incidence ratio [SIR] = 76.4).4 High
HIV plasma viral load, absence of antiretroviral therapy
(ART) as well as low CD4+ T-cell counts are known pre-
dictive factors for NHL.7,8 The introduction of ART into
clinical practice has led to improved overall survival and
restoration of immunity by decreasing viral load and
increasing CD4+ T-cell counts, and has led to a decreased
risk of developing NHL. However, the risk remains sub-
stantially elevated compared to the general population
(suboptimal immune response [SIR] 9.1[range, 8.3–10.1])9
and NHL still represents 20% of all cancers in people liv-
ing with HIV in the ART era.10 NHL associated with HIV
are predominantly aggressive B-cell lymphomas.
Although they are heterogeneous, they share several
pathogenic mechanisms involving chronic antigen stimu-
lation, impaired immune response, cytokine deregula-
tion and reactivation of the oncogenic viruses EBV and
HHV-8.11
The emergence of genome-wide approaches in human
genomics has led to the discovery of many associations
between common genetic polymorphisms and suscepti-
bility to several diseases including HIV infection and
multiple types of cancer.12,13 Recent genome-wide associ-
ation studies (GWAS) of NHL have identified multiple
susceptibility loci in the European population.14–22 These
variants are located in the genes LPXN21, BTNL223,
EXOC2, NCOA114, PVT114,22, CXCR5, ETS1, LPP, and
BCL222 for various subtypes of NHL, as well as BCL6 in
the Chinese population.24 Strong associations with varia-
tion in human leukocyte antigen (HLA) genes have also
been reported.15,18,22 However, in the setting of HIV infec-
tion, no genome-wide analysis has been reported con-
cerning the occurrence of NHL and the specific mecha-
nisms driving their development remain largely
unknown.
Here we report the results of the first genome-wide
analysis of NHL susceptibility in individuals chronically
infected with HIV. We combined three HIV cohort stud-
ies from France, Switzerland and the USA and searched
for associations between >6 million single nucleotide
polymorphisms (SNP) and a diagnosis of NHL. We iden-
tified a novel genetic locus near CXCL12 to be associated
with the development of NHL among HIV+ individuals.
Methods
Ethics statement
The SHCS, the Primo ANRS and ANRS CO16 Lymphovir
cohorts (ANRS) and the Multicenter AIDS Cohort Study
(MACS) cohorts have been approved by the competent Ethics
Committees /Institutional Review Boards of all participating
institutions. A written informed consent, including consent for
human genetic testing, was obtained from all study partici-
pants. 
Study participants and contributing centers
Genotyping and phenotypic data were obtained from a total
of 2,202 HIV+ individuals enrolled in the SHCS, ANRS and
MACS cohorts (278 cases and 1,924 controls) (Table 1). For
details on inclusion criteria and cohorts, refer to the Online
Supplementary Appendix. 
Quality control and imputation of genotyping data
The genotyping data from each cohort was filtered and
imputed in a similar way, with each genotyping array processed
separately to minimize potential batch effects. All variants were
first flipped to the correct strand orientation with BCFTOOLS
(v1.8) using the human genome build GRCh37 as reference.
Variants were removed if they had a larger than 20% minor
allele frequency (MAF) deviation from the 1,000 genomes phase
3 EUR reference panel or if they showed a larger than 10%
MAF deviation between genotyping chips in the same cohort.
The quality control (QC) filtered genotypes were phased
with EAGLE225 and missing genotypes were imputed using
PBWT26 with the Sanger Imputation Service,27 taking the 1,000
genomes project phase 3 panel as reference. Only high-quality
variants with an imputation score (INFO >0.8) were retained
for further analyses.
Genome-wide association testing and meta-analysis
In order to search for associations between human genomic
variation and the development of HIV-related NHL, we first
performed separate GWAS within each cohort (SHCS, ANRS
and MACS) prior to combining the results in a meta-analysis.  
For each cohort separately, the imputed variants were filtered
out using PLINK (v2.00a2LM)28 based on missingness (>0.1),
MAF (<0.02) and deviation from Hardy-Weinberg Equilibrium
(PHWE<1e-6). Determination of population structure and calcula-
tion of principal components was done using EIGENSTRAT
(v6.1.4)29 and the HapMap3 reference panel.30 All individuals not
clustering with the European HapMap3 samples were excluded
from further analyses. The samples were screened using KING
(v2.1.3)31 to ensure no duplicate or cryptic related samples were
included. Single-marker case-control association analyses were
performed using linear mixed models, with genetic relationship
matrices calculated between pairs of individuals according to the
leave-one-chromosome-out principle, as implemented in GCTA
mlma-loco (v1.91.4beta).32,33 Sex was included as a covariate,
except in the MACS cohort, which only includes men.
The results of the three GWAS were combined across cohorts
using a weighted Z-score-based meta-analysis in PLINK
(v1.90b5.4), after exclusion of the variants that were not present
in all three cohorts.  
Other methods
The details of the cohorts and other methods used, i.e., fine
mapping, prediction of causal variants, long-range chromatin
interactions, transcriptomic effects, comparisons to GWAS in
the general population and information on data sharing can be
found in the Online Supplementary Appendix. 
Results
Study participants and association testing
In order to identify human genetic determinants of
HIV-associated NHL, we performed case-control GWAS
in three groups of HIV+ patients of European ancestry
(SHCS, ANRS and MACS). The characteristics of the
study participants are presented in Table 1. In total, geno-
typing data were obtained for 278 cases (NHL+/HIV+)
and 1,924 matched controls (NHL-/HIV+). With this sam-
ple size, we had 80% power to detect a common genetic
variant (10% minor allele frequency) with a relative risk
of 2.5, assuming an additive genetic model and using
Bonferroni correction for multiple testing (Pthreshold=5e-8).34
After genome-wide imputation and quality control, 6.2
million common variants were tested for association with
the development of NHL using linear mixed models
including sex as a covariate. Results were combined
across cohorts using a weighted Z-score-based meta-
analysis (Figure 1A). The genomic inflation factor (lamb-
da) was in all cases very close to 1 [1.00–1.01], indicating
an absence of systematic inflation of the association
results (Figure 1B; Online Supplementary Figure S2).
Association results
We observed significant associations with the develop-
ment of HIV-related NHL at a single locus on chromo-
some 10, downstream of CXCL12 (Figure 1C). A total of
seven SNP in this locus had P-values lower than the
genome-wide significance threshold (P<5e-8), with
rs7919208 displaying the strongest association (Table 2).
This association was only detected in the SHCS and
ANRS cohorts and not among MACS study participants
(Online Supplementary Table S1). 
Fine mapping of the CXCL12 locus 
In order to identify the causal variant(s) among associ-
ated SNP and determine their potential functional effects,
we used a multi-level fine mapping approach, combining
the statistical fine mapping tool PAINTOR to obtain a
99% credible set and the deep learning framework
DeepSEA to predict any effects on chromatin marks and
transcription factor binding these variants may have.
Using PAINTOR, we identified a single variant,
rs7919208, having a high posterior probability (=100%)
of being causal among the 99% credible set based on the
integration of the association results, linkage disequilibri-
um (LD) structure and enrichment of genomic features in
this locus (Figure 2). 
Consistent with the PAINTOR result, DeepSEA also
identified rs7919208 as the sole variant, among the 99%
credible set, predicted to have a functional impact by sig-
nificantly increasing the probability of binding by the B-
cell transcription factors BATF (log2 fold-change=3.27) and
JUND (log2 fold-change=2.91) (Online Supplementary Table
S2). Further analysis of the genomic sequence surrounding
rs7919208 and the JASPAR transcription factor binding site
(TFBS) motifs for BATF and JUND revealed that rs7919208
G->A polymorphism creates the TFBS motif required for
the binding of these transcription factors (Figure 3A). 
Long-range chromatin interactions
In order to assess the potential functional links between
the TFBS created in the presence of the minor allele of
rs7919208 and the nearby genes, we performed an analy-
sis of promoter capture Hi-C data and topologically asso-
ciating domains (TAD). We used the well-characterized
GM12878 lymphoblastoid cell line produced by EBV
transformation of B lymphocytes collected from a female
European donor as a model. 
First, in order to examine the interaction potential of
the rs7919208 region with nearby promoters, we ana-
lyzed available promoter capture Hi-C data obtained
from the GM12878 cell line. This analysis revealed a sig-
nificant interaction between the rs7919208 region and the
CXCL12 promoter, suggesting a possible modulating
impact of rs7919208 on the transcription of that gene
(Figure 3B). Second, in order to further validate this
observed genomic interaction, we analyzed available
TAD calls from GM12878 cells,35 using the 3D Genome
Browser for visualization36 (Figure 3C). We observed that
rs7919208 is located within a large TAD together with
CXCL12, signifying the interaction potential of the new
TFBS at rs7919208 and CXCL12. 
Transcriptomic effects of rs7919208
We did not observe any association between rs7919208
and mRNA expression levels of CXCL12 in peripheral
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Table 1. Summary of included samples and studies.
Cohort                                Cases               Controls             Lambda          Genotyping                                Years of                  Control
                                                                                                                   chips                                     NHL diagnosis              inclusion criteria
SHCS                                           145                         1,090                       1.00               Illumina                                           2000 - 2017                    HIV < 2005, no cancer 
Age (median)                         61                            58                                                HumanOmniExpress-24,                                                      diagnosis as of 2017 & 
Sex (male, %)                       91%                         80%                                              Human1M, Human610,                                                         matched with age
                                                                                                                                            HumanHap550, 
                                                                                                                                            HumanCore-12                                                                       
ANRS                                      61                           562                        1.00               Illumina Human Omni5                2008 - 2015                    No cancer diagnosis
Age (median)                         50                            34                                                Exome 4v 1-2, 
Sex (male, %)                       89%                         87%                                              Illumina 300
MACS                                     72                           272                        1.01               Illumina 1MV1,                               1985 - 2013                    Matched to cases in 
Age (median)                         69                            68                                                Human1M-Duo,                                                                      terms of age, treatment &
Sex (male, %)                      100%                       100%                                             HumanHap550                                                                        time of infection
Cohort and patient characteristics for the Swiss HIV Cohort Study (SHCS), the Primo ANRS and ANRS CO16 Lymphovir cohorts (ANRS) and the Multicenter AIDS Cohort Study
(MACS) cohorts. Lambda indicates the genomic inflation factor from the individual cohort genome-wide association studies (GWAS). NHL: non-Hodgkin lymphoma; HIV: human
immunodeficiency virus.
blood or peripheral blood mononuclear cells (PBMC)
from multiple publicly available datasets, including
GTEx,37 GEUVADIS38 and the Milieu Intérieur
Consortium39 (Online Supplementary Figure S3). Of note,
CXCL12 expression levels were very low in all datasets
(Online Supplementary Figure S4A).
Using allele-specific expression analysis in the GTEx
dataset, we observed a significant effect in individuals
heterozygous of rs7919208, with increased allelic imbal-
ance of CXCL12 in fibroblasts (false discovery rate
adjusted P=0.0006, one-sided rank sum test), which was
not observed in other tissues (Online Supplementary
Figure 4B). 
HIV infection causes many profound transcriptomic
changes.40 Thus, in order to examine the effect of
rs7919208 on CXCL12 in the context of HIV infection, we
extracted RNA from PBMC of 452 individuals in the
SHCS with available genotyping data and sequenced
them using the Bulk RNA Barcoding and sequencing
(BRB-seq) approach.41 However, the expression levels of
CXCL12 were below the limit of detection for most indi-
viduals, preventing an expression quantitative trait loci
(eQTL) analysis. 
Multiple isoforms of CXCL12 exist, with variable
degrees of expression and potency described in the con-
text of HIV infection.42 We observed a single significant
correlation between rs7919208 and CXCL12 transcript
usage, which was restricted to visceral adipose tissue.
The presence of the rs7919208 minor allele was associat-
ed with higher relative expression of the longer and rarer
transcript isoform ENST00000374429.6 (Online
Supplementary Figure S5).
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Figure 1. Genome-wide association analysis. (A) Schematic of analysis pipeline. (B) Quantile-quantile plot of the observed -log10(P-value) (black dots, y-axis) vs. expect-
ed -log10(P-values) under the null hypothesis (red line) to check for any genomic inflation of the observed P-values. No genomic inflation is observed, with the genomic
inflation factor λ=0.99. (C) Manhattan plot of all obtained P-values for each variant included in the meta-analysis. The genome-wide threshold (P=5e-8) for signifi-
cance is marked by a dotted line. Only variants at the CXCL12 locus were found to be significant. 
No replication of susceptibility loci found in the 
general population
In order to assess whether the genetic contribution to
the risk of developing NHL is similar or distinct in the
HIV+ population compared to the general population, we
extracted the P-values of all variants found to be genome-
wide significant in previous GWAS performed in the gen-
eral population14,21–24,43 and compared them to our results.
We did not replicate any of the previously published
genome-wide associated variants, even at nominal signifi-
cance level (P<0.05), despite sufficient statistical power for
many of the variants, thus indicating that the genetic sus-
ceptibility of NHL is distinct between the HIV+ and the
general population (Online Supplemental Table S3). In order
to further examine this possibility, we tested whether the
NHL/HIV+ associated variant rs7919208 is associated
A
B
Figure 2. Fine mapping of genome-
wide significant hits with PAINTOR.
(A) The 99% credible set and poste-
rior probabilities of being the
causal variant. The genomic posi-
tions are listed on the x-axis.
Bottom tracks represent DNAase
and chromatin marks obtained
from GM12878 cells as well as
transcription factor binding site
(TFBS) from the Roadmap
Epigenomics Project and ENCODE
in the region. (B) Locus plot of the
associated variants, highlighting
the LD relationship, based on the
Swiss HIV Cohort Study cohort. The
top variant rs7919208 is marked
by a black diamond.
Table 2. Significant association with human immunodeficiency virus-related
non-Hodgkin lymphoma.
Chr           Pos                   SNP                Ref             Alt                  P            OR
10            44673557             rs7919208                A                   G                 4.77e-11        1.23
10            44677967           rs149399290              T                   C                 3.09e-08        1.20
10            44678218            rs17155463               T                   A                 3.09e-08        1.20
10            44678262            rs17155474               C                   T                 3.09e-08        1.20
10            44678454            rs17155478               T                   C                 3.09e-08        1.20
10            44678898            rs12249837              G                   A                 3.09e-08        1.20
10            44680902            rs10608969               T             TAAAGA           3.09e-08        1.20
Variants significantly associated with human immunodeficiency virus (HIV)-related non-
Hodgkin lymphoma in a weighted Z-score-based meta-analysis of all individuals included in
the Swiss HIV Cohort Study (SHCS), the Primo ANRS and ANRS CO16 Lymphovir cohorts
(ANRS) and the Multicenter AIDS Cohort Study (MACS) cohorts. Odds ratios (OR) were trans-
formed from betas using the formula OR=exp(beta). Chr: chromosome; pos: position; SNP: sin-
gle nucleotide polymorphisms; Ref: reference allele, Alt: alternative allele.
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Figure 3. Novel transcription factor binding site and long-range interactions. (A) Canonical motifs of BATF and JUND with the underlying genomic reference sequence
and the nucleotide change caused by rs7919208. (B) Promoter capture Hi-C analysis in the GM12878 cell line of the region with the predicted causal variant and
CXCL12. Variants and their level of association in the meta-analysis are marked in the inner grey circle. Genome-wide significant variants are colored green. Purple lines
indicate significant interactions between promoter and other genomic regions. (C) Topologically associating domains (TAD) in the GM12878 cell line in the region of
CXCL12. The yellow and blue boxes indicate the called TAD from the Hi-C contact map above. The plot is centered on rs7919208. DHS: DNase I hypersensitive sites.
with an increased risk of NHL in the general population.
We performed a series of case/control GWAS of four NHL
subtypes (CLL, DLBCL, FL and MZL) as well as a com-
bined GWAS with all NHL subtypes (Online Supplementary
Table S4; Online Supplementary Figure S6) and assessed the
association evidence at rs7919208. We found no associa-
tion between rs7919208 and any of the subtypes in the
general population, even at nominal significance.
Discussion
In this genome-wide analysis, including a total of 278
NHL HIV+ cases and 1,924 HIV+ controls from three
independent cohorts, we identified a novel NHL suscep-
tibility locus on chromosome 10 near the CXCL12 gene.
The strong signal observed in the meta-analysis was driv-
en by the associations detected in the SHCS and ANRS
cohorts and there was no evidence of association in the
MACS cohort. Notably, most NHL cases in the MACS
cohort date back to the pre-ART era, while only NHL
cases diagnosed after the year 2000 were included in the
SHCS and ANRS analyses. Conceivably, NHL occurring
in the early years of the HIV pandemic may have been
primarily driven by severe immunosuppression, which
could have obscured any influence of human genetic vari-
ation among the cases in the MACS sample. Precise phe-
notype definition is crucial in designing large-scale genet-
ic studies since any environmental noise tends to decrease
the likelihood of identifying potential genetic influences.
NHL is a relatively rare cancer even among HIV infect-
ed individuals, making it difficult to collect the large num-
bers of cases that would typically be included in contem-
porary genome-wide genetic studies. Indeed, a recent
study from the Data Collection on Adverse events of
Anti-HIV Drugs (D:A:D) group showed an NHL inci-
dence rate of 1.17/1,000 person-years of follow-up over
the past 15 years (392 new cases in >40,000 HIV+ individ-
uals).8 Still, we were able to obtain clinical and genetic
data from a total of 278 patients with confirmed NHL
diagnosis. By matching them with a larger number of
controls from the same cohorts, we had enough power to
identify associated variants of relatively large effects in
the CXCL12 region.  
Several groups have already suggested a potential role
for CXCL12 variation in HIV-related NHL. A prospective
study correlated increased CXCL12 expression with sub-
sequent NHL development in HIV+ children but not in
uninfected children.44 The number of A alleles at the
CXCL12-3’ variant (rs1801157) has also previously been
associated with an increased risk of developing HIV-relat-
ed NHL during an 11.7 year follow-up period.45 Thus, our
data further support the role of CXCL12 as a critical mod-
ulator of the individual risk of developing NHL in the
HIV+ population. 
The role of CXCL12 and its receptor chemokine recep-
tor 4 (CXCR4) in cancer in the general population is well
established, with the levels of CXCL12 and CXCR4 found
to be increased in multiple types of cancer and to be asso-
ciated with tumor progression.46,47 Furthermore, in vivo
inhibition of either CXCR4 or CXCL12 signaling is capa-
ble of disrupting early lymphoma development in severe
combined immunodeficient (SCID) mice transfused with
EBV+ PBMC.48 These results and others have already led
to the development and testing of several small molecules
targeting either CXCL12 or CXCR4 to inhibit tumor pro-
gression.46
We could not identify any significant relationship
between rs7919208 and the expression levels of CXCL12
in PBMC or EBV transformed lymphocytes. This could be
due to the low expression levels of CXCL12 in most tis-
sues, apart from stromal cells. Still, our analysis of allele-
specific expression showed a significant allelic imbalance
for heterozygous carriers of rs7919208 for CXCL12. This
signal was only observed in fibroblasts, the GTEx tissue
most closely resembling stromal cells. Furthermore, we
identified a significant association between rs7919208
and CXCL12 transcript isoform usage in the visceral adi-
pose tissue, which is known to also contain a minority of
stromal cells.49 Combined these results underscore the
potential importance of these cells in the development of
HIV-related NHL and the ability of rs7919208 to modify
transcription.
The new BATF and JUND binding site created by
rs7919208 could act as an induced or dynamic eQTL,
specifically triggered by HIV infection. Such eQTL can be
found in regions deprived of regulatory annotations, since
these have been mostly examined in static cell types.50
Supporting this hypothesis, HIV has been shown to
induce overexpression of BATF.51 This would explain why
rs7919208 is only a risk factor for HIV+ individuals and
not in the general population.
Previous analyses in the general population have discov-
ered both shared and distinct associations for NHL sub-
types.14,21–24,43 However, similar analyses were not possible
in our sample since NHL subtype information was not
available for many of our cases. Furthermore, information
on serostatus for relevant co-infections with EBV or other
oncogenic viruses was not available and could therefore
not be assessed. In particular, EBV has been largely associ-
ated with the development of NHL and other lymphomas
and is considered a driver of a subset of NHL in the general
population.52 Variants in the HLA region have consistently
been associated with all NHL subtypes in HIV uninfected
populations regardless of EBV serostatus, although differ-
ent HLA associations have been observed for each NHL
subtype. We did not find any evidence of HLA associations
in our analyses of HIV-related NHL. This might be due to
a lack of power, due to our limited sample size in compar-
ison to the NHL GWAS performed in the general popula-
tion. However, this lack of replication of HLA variants and
all other risk variants previously identified in the general
population strongly suggests that distinct genes or path-
ways influence susceptibility to NHL in the HIV+ popula-
tion compared to the general population.53 This distinction
may be due to the unique pathogenic mechanisms
involved in HIV-associated NHL, such as cytokine deregu-
lation, chronic antigen stimulation and impaired immune
response, among others.11
In summary, we have identified variants significantly
associated with the development of NHL in the HIV+
population. Fine mapping of the associated locus and sub-
sequent analyses of TAD, promoter capture Hi-C data as
well as deep-learning models of mutational effects on
transcription factor binding, points to a causative model
involving the gain of a BATF and JUND transcription
binding site downstream of CXCL12 capable of physical-
ly interacting with the CXCL12 promoter. These results
suggest an important modulating role of CXCL12 in the
development of HIV-related NHL. 
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